Scholarlink

Background <p>Due to lack of early biomarkers, pancreatic cancer (PanCa), often manifests late, with few treatment options and poor prognosis, Although epigenetic regulators—particularly lysine methyltransferases like <i>KMT2C</i>—are becoming increasingly linked to cancer biology, their function in PanCa is still poorly understood.</p> Objectives <p>This study aims to investigate <i>KMT2C’s</i> mutational and expression landscape in Indian PanCa patients, to explore it’s possible role in carcinogenesis and immune modulation, and to assess its druggability through computational docking and dynamic simulations.</p> Methods <p>Clinical samples from Indian PanCa patients were used for differential expression and mutation studies. Differential expression, methylation, mutation, and immune cell infiltration profiling were also conducted using public databases (TCGA, GEO, CPTAC, and CCLE). Regulatory networks, scRNA-seq analysis, and protein–protein interaction networks were mapped. To evaluate ligand binding to <i>KMT2C</i>, molecular docking and 100-ns molecular dynamics simulations were used.</p> Results <p><i>KMT2C</i> was overexpressed and exhibited a significantly higher mutational frequency (62.5%) in Indian PanCa samples in contrast with Western cohorts. Its role in immune suppression was implicated by positive correlations observed between <i>KMT2C</i> expression and several.</p> <p>immune-checkpoint receptor expression and regulatory T-cell infiltration. <i>KMT2C</i> was connected by functional enrichment to inositol phosphate metabolism and chromatin remodelling. The therapeutic potential of protodioscin was suggested by its strong binding affinity to KMT2C and the formation of stable interactions confirmed by MD simulations.</p> Conclusion <p>This study suggests <i>KMT2C</i> to be a putative oncogene in Indian PanCa patients in contrast with Western PanCa patients, with immunomodulatory effects and therapeutic potential, implicating its role as a promising biomarker, requiring additional clinical validation, emphasizing the necessity of ethnically informed precision oncology.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Identification of a chromatin-modifying gene-histone lysine N-methyl transferase (KMT2C/MLL3) as a potential immunomodulator oncogene in Indian pancreatic cancer patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月14日

查看全文
  • Sounetra Choudhury,
  • Akash Bararia,
  • Arunima Maiti,
  • Sayan Saha,
  • Sumit Mukherjee,
  • Shuchismita Chakraborty,
  • Arnab Pal,
  • Shibajyoti Ghosh,
  • Bitan K. Chattopadhay,
  • Sudeep Banerjee,
  • Supriyo Ghatak,
  • Debabrata Ghosh Dastidar,
  • Nilabja Sikdar

摘要

Background

Due to lack of early biomarkers, pancreatic cancer (PanCa), often manifests late, with few treatment options and poor prognosis, Although epigenetic regulators—particularly lysine methyltransferases like KMT2C—are becoming increasingly linked to cancer biology, their function in PanCa is still poorly understood.

Objectives

This study aims to investigate KMT2C’s mutational and expression landscape in Indian PanCa patients, to explore it’s possible role in carcinogenesis and immune modulation, and to assess its druggability through computational docking and dynamic simulations.

Methods

Clinical samples from Indian PanCa patients were used for differential expression and mutation studies. Differential expression, methylation, mutation, and immune cell infiltration profiling were also conducted using public databases (TCGA, GEO, CPTAC, and CCLE). Regulatory networks, scRNA-seq analysis, and protein–protein interaction networks were mapped. To evaluate ligand binding to KMT2C, molecular docking and 100-ns molecular dynamics simulations were used.

Results

KMT2C was overexpressed and exhibited a significantly higher mutational frequency (62.5%) in Indian PanCa samples in contrast with Western cohorts. Its role in immune suppression was implicated by positive correlations observed between KMT2C expression and several.

immune-checkpoint receptor expression and regulatory T-cell infiltration. KMT2C was connected by functional enrichment to inositol phosphate metabolism and chromatin remodelling. The therapeutic potential of protodioscin was suggested by its strong binding affinity to KMT2C and the formation of stable interactions confirmed by MD simulations.

Conclusion

This study suggests KMT2C to be a putative oncogene in Indian PanCa patients in contrast with Western PanCa patients, with immunomodulatory effects and therapeutic potential, implicating its role as a promising biomarker, requiring additional clinical validation, emphasizing the necessity of ethnically informed precision oncology.